title: Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response.
abstract: The influence of age and administered daily dosage on the plasma concentrations of gabapentin (GBP) at steady state was evaluated in a group of 41 children and young adults (aged 3-30 years) receiving long-term adjunctive treatment with GBP for the management of refractory partial-onset seizures. For each patient, peak and trough concentrations were determined by a specific high-performance liquid chromatography (HPLC) method in samples obtained before the morning dose and 2.5 hours later, respectively. To assess within-subject relationship between plasma concentration and dosage, 30 patients were evaluated at more than one dosage level. Within the assessed dose range, plasma GBP concentrations were linearly related to dose. Apparent oral clearance values (mean +/- SD) in children aged 6 years or less (4.8 +/- 0.9 mL/kg/min) were comparable with those observed in children aged 7 to 15 years (4.6 + 1.5 mL/kg/min) and moderately higher than those found in young adults (3.9 + 0.9 mL/kg/min), even though differences among groups failed to reach statistical significance. There was, however, a significant difference in CL/F between children aged 10 years or less and older children (5.1 +/- 1.1 vs. 3.8 +/- 1.2 mL/kg/min, P < 0.005). Of the 41 patients who entered the study, 22 discontinued treatment, mostly due to insufficient efficacy. No significant difference in plasma GBP concentration was detected between patients showing a greater than 50% reduction in seizure frequency (4.1 +/- 1.9 microg/mL, n = 11, mean +/- SD) and those having no significant clinical improvement (4.4 +/- 1.7 microg/mL, n = 30). These results indicate that in children given dosages up to 50 mg/kg/d (mean, 25 mg/kg/d), GBP pharmacokinetic analyses show no important deviation from linearity. The data also suggest that, on average, children may need moderately higher dosages to reach plasma GBP concentrations comparable with those found in adults. There seems to be a large variation in the plasma concentrations of the drug associated with a favorable therapeutic response.
authors.affiliation: Department of Internal Medicine and Therapeutics, University of Pavia, Italy. gatti@unipv.it
authors.forename: Giuliana
authors.initials: G
authors.lastname: Gatti
authors.forename: Anna Rita
authors.initials: AR
authors.lastname: Ferrari
authors.forename: Renzo
authors.initials: R
authors.lastname: Guerrini
authors.forename: Paolo
authors.initials: P
authors.lastname: Bonanni
authors.forename: Ilaria
authors.initials: I
authors.lastname: Bonomi
authors.forename: Emilio
authors.initials: E
authors.lastname: Perucca
mesh_terms: D000085:Acetates / Q000008:administration & dosage* / Q000097:blood*; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000588:Amines; D000704:Analysis of Variance; D002648:Child; D002675:Child, Preschool; D003509:Cyclohexanecarboxylic Acids; D004305:Dose-Response Relationship, Drug; D004827:Epilepsy / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008297:Male; D018709:Statistics, Nonparametric; D005680:gamma-Aminobutyric Acid
chemical_list: D000085:Acetates; D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin